[1]王 龙.甲氨蝶呤联合羟氯喹对类风湿性关节炎患者关节肿胀及晨僵症状的影响[J].医学信息,2024,37(16):96-99.[doi:10.3969/j.issn.1006-1959.2024.16.021]
　WANG Long.Effect of Methotrexate Combined with Hydroxychloroquine on Joint Swellingand Morning Stiffness in Patients with Rheumatoid Arthritis[J].Journal of Medical Information,2024,37(16):96-99.[doi:10.3969/j.issn.1006-1959.2024.16.021]
点击复制

甲氨蝶呤联合羟氯喹对类风湿性关节炎患者关节肿胀及晨僵症状的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年16期
页码:
96-99
栏目:
论著
出版日期:
2024-08-15

文章信息/Info

Title:
Effect of Methotrexate Combined with Hydroxychloroquine on Joint Swellingand Morning Stiffness in Patients with Rheumatoid Arthritis
文章编号:
1006-1959（2024）16-0096-04
作者:
王 龙
吉安县人民医院风湿免疫科，江西 吉安 343100
Author(s):
WANG Long
Rheumatism Immunity Department of Ji’an County People’s Hospital,Ji’an 343100,Jiangxi,China
关键词:
甲氨蝶呤; 羟氯喹; 类风湿性关节炎; 关节肿胀; 晨僵症状
Keywords:
Methotrexate; Hydroxychloroquine; Rheumatoid arthritis; Joint swelling; Morning stiffness symptoms
分类号:
R593.22
DOI:
10.3969/j.issn.1006-1959.2024.16.021
文献标志码:
A
摘要:
目的 研究甲氨蝶呤联合羟氯喹对类风湿性关节炎患者关节肿胀及晨僵症状的影响。方法 选取2019年3月-2022年3月我院诊治的61例类风湿性关节炎患者为研究对象，采用随机数字表法分为对照组（n=30）和观察组（n=31）。对照组采用甲氨蝶呤治疗，观察组在对照组基础上联合羟氯喹治疗，比较两组临床疗效、关节肿胀评分、晨僵时间、疼痛评分（VAS）、超敏C反应蛋白（hs-CRP）和红细胞沉降率（ESR）水平、不良反应发生率。结果 观察组治疗总有效率为93.55%，高于对照组的83.33%（P＜0.05）；两组治疗后关节肿胀评分低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后VAS评分均低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后晨僵时间均短于治疗前，且观察组短于对照组（P＜0.05）；两组治疗后hs-CRP、ESR水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为9.68%，低于对照组的20.00%（P＜0.05）。结论 甲氨蝶呤联合羟氯喹治疗可减轻类风湿性关节炎患者关节肿胀程度，缩短晨僵时间，减轻患者疼痛度，降低hs-CRP、ESR水平及不良反应发生率，是一种可行、安全、有效的治疗方案。
Abstract:
Objective To study the effect of methotrexate combined with hydroxychloroquine on joint swelling and morning stiffness in patients with rheumatoid arthritis.Methods A total of 61 patients with rheumatoid arthritis diagnosed and treated in our hospital from March 2019 to March 2022 were selected as the research objects. They were divided into control group (n=30) and observation group (n=31) by random number table method. The control group was treated with methotrexate, and the observation group was treated with hydroxychloroquine on the basis of the control group. The clinical efficacy, joint swelling score, morning stiffness time, pain score (VAS), high-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) levels, and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.55%, which was higher than 83.33% in the control group (P<0.05). The joint swelling score of the two groups after treatment was lower than that before treatment, and that of the observation group was lower than that of the control group (P<0.05). The VAS score of the two groups after treatment waslower than that before treatment, and that of the observation group was lower than that of the control group (P<0.05). The morning stiffness time of the two groups after treatment was shorter than that before treatment, and that of the observation group was shorter than that of the control group (P<0.05). After treatment, the levels of hs-CRP and ESR in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 9.68%, which was lower than 20.00% in the control group(P<0.05).Conclusion Methotrexate combined with hydroxychloroquine can reduce the degree of joint swelling in patients with rheumatoid arthritis, shorten the time of morning stiffness, reduce the pain of patients, reduce the levels of hs-CRP and ESR and the incidence of adverse reactions. It is a feasible, safe and effective treatment.

参考文献/References:

[1]汪陶荣,张晔,曹威,等.白藜芦醇通过下调MnSOD 诱导类风湿性关节炎成纤维样滑膜细胞凋亡[J].中国药理学通报,2019,35(4):489-494.[2]贾庆运,王拥军,梁倩倩,等.槲皮素对人类风湿性关节炎成纤维样滑膜细胞炎症因子和基质金属蛋白酶的表达的影响[J].中国骨质疏松杂志,2019,25(6):738-741.[3]罗伟,马丽辉,邓黎黎,等.IL-33和IL-17在类风湿性关节炎合并间质性肺病中的表达及临床意义[J].临床肺科杂志,2019,24(3):416-419.[4]彭志平,杨华娟,林云.二维应变率成像在类风湿性关节炎患者左心房功能评价的效果观察[J].福建医药杂志,2019,41(2):10-12.[5]彭泽学,刘立志,刘广保,等.早期类风湿性关节炎患者影像学改变与乌头汤加减线性关系的临床研究[J].辽宁中医杂志,2019,46(5):1008-1012.[6]Niewiński G,Graczyńska A,Morawiec S,et al.Renaissance of Modified Charlson Comorbidity Index in Prediction of Short and Long-Term Survival After Liver Transplantation[J].Med Sci Monit,2019,25:4521-4526.[7]李荣良,沈贤发,薛鸾.甲氨蝶呤联合硫酸羟氯喹治疗类风湿性关节炎中医不同证型疗效分析[J].河南中医,2017,37(11):1975-1977.[8]罗成城.藤莓汤联合来氟米特、甲氨蝶呤治疗热毒瘀阻型类风湿关节炎的疗效观察[J].中国基层医药,2019,26(23):2840-2843.[9]李学荣,张榜硕,陈永平.艾拉莫德联合依那西普治疗难治性类风湿性关节炎的临床疗效研究[J].安徽医药,2019,23(8):1674-1677. [10]林静,于慧敏,王涛.姜黄素联合甲氨蝶呤治疗类风湿关节炎骨破坏的疗效观察[J].天津中医药,2019,36(3):238-241.[11]盖楠楠,张薇.甲泼尼龙联合甲氨蝶呤治疗类风湿关节炎临床疗效及作用机制研究[J].药物评价研究,2018,41(11):2082-2085.[12]王莎莎,吴斌,邵勤,等.艾拉莫德阶段性联合甲泼尼龙和甲氨蝶呤治疗类风湿关节炎伴白细胞减少的临床观察[J].新医学,2017,48(2):114-117.[13]高鹏,霍爱鑫,刘宇宏.雷公藤多苷联合甲氨蝶呤治疗类风湿性关节炎的疗效[J].西部医学,2017,29(11):1511-1515.[14]Zhao Z,Hua Z,Luo X,et al.Application and pharmacological mechanism of methotrexate in rheumatoid arthritis[J].Biomed Pharmacother,2022,150:113074.[15]张欣,刘峰,姬敏.塞来昔布治疗类风湿关节炎疗效与安全性分析[J].社区医学杂志,2020,18(6):425-428.[16]李碧艳,宋祖栏.来氟米特联合甲氨蝶呤在类风湿性关节炎治疗的临床应用效果与安全性[J].临床合理用药杂志,2022,15(11):86-89.[17]于芳,南方.类风湿关节炎患者血清炎性因子与C反应蛋白和疾病活动度评分的相关性分析[J].国际免疫学杂志,2018,41(6):644-647.[18]李雪娜.甲氨蝶呤-金纳米靶向制剂的制备及其治疗类风湿性关节炎的研究[D].延吉:延边大学,2022.[19]陈婷,何治中.补肾通络方联合西药治疗类风湿性关节炎继发骨质疏松的临床疗效[J].医学理论与实践,2018,31(4):529-531.[20]孙康文,罗刚.甲氨蝶呤联合阿达木单抗治疗早期类风湿性关节炎患者的效果及对血清CD206含量的影响[J].医学信息,2020,33(23):141-143.

更新日期/Last Update: 1900-01-01